Next |
home / stock / immx / immx message board
Subject | By | Source | When |
---|---|---|---|
znewcar1: $IMMX 24% v3,1M c2.30 f13,898M H2.39 ML1.51 | znewcar1 | investorshangout | 04/27/2023 8:46:40 PM |
Thank you, bro, this one needs a pin | subslover | investorshub | 04/27/2023 9:43:09 AM |
$IMMX 5:30 NEWS https://finance.yahoo.com/news/nexcella-immix-biopharma-subsidiar | TheFinalCD | investorshub | 04/26/2023 9:56:46 PM |
N excella, an Immix Biopharma subsidiary, Announces Positive | Awl416 | investorshub | 04/26/2023 9:33:44 PM |
Play the volume spikes an thats it or | harry crumb | investorshub | 03/29/2023 2:00:43 PM |
This wont move much for the next 18 | harry crumb | investorshub | 03/29/2023 2:00:14 PM |
News | Awl416 | investorshub | 03/23/2023 12:01:53 PM |
These are cheap | harry crumb | investorshub | 03/10/2023 6:53:45 PM |
Cant hurt to add more here at 2 | harry crumb | investorshub | 03/09/2023 12:49:56 PM |
Another buying opp. Here | harry crumb | investorshub | 02/28/2023 1:43:59 PM |
Ditto harry. :) | subslover | investorshub | 02/23/2023 2:52:21 AM |
Here to $$$$ | harry crumb | investorshub | 02/22/2023 10:18:36 PM |
Picking up some $MOJO! | subslover | investorshub | 02/22/2023 2:22:07 PM |
Added more 2.20s | harry crumb | investorshub | 02/18/2023 4:18:04 AM |
Still adding this ticker | harry crumb | investorshub | 02/16/2023 2:15:43 AM |
2.50 adding here | harry crumb | investorshub | 02/13/2023 4:30:56 PM |
$IMMX........................................https://stockcharts.com/h-sc/ui?s=IM | glenn1919 | investorshub | 02/10/2023 9:24:29 PM |
$38M mkt cap. | IPO$ | investorshub | 02/10/2023 3:09:56 PM |
Ton of cash here. | IPO$ | investorshub | 02/10/2023 3:07:55 PM |
Pulled back | harry crumb | investorshub | 02/07/2023 11:02:46 PM |
News, Short Squeeze, Breakout and More Instantly...
Immix Biopharma Inc. Company Name:
IMMX Stock Symbol:
NASDAQ Market:
LOS ANGELES, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announc...
LOS ANGELES, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq:IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company advancing personalized therapies for oncology and immunology, today announce...
NEXICART-2 to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to U.S. sites based on IND clearance 72 patients previously dosed with NXC-201 ex-U.S. First CAR-T program for light-chain (AL) Amyloidosis Favorable tolerability enables expansion into autoimmune indication...